While it is indeed the case that the current administration has made drug pricing and biosimilars a priority, and while the Biosimilar Action Plan was hailed as a major step forward for biosimilars in the United States, “It’s not the only plan that’s going to exist,” said the FDA's Leah Christl, PhD.
During the fifth DIA Biosimilars Conference, held October 22 to 23, 2018, in London, United Kingdom, Leah Christl, PhD, associate director for therapeutic biologics, director of the therapeutic biologics and biosimilars staff in the office of new drugs in the FDA’s Center for Drug Evaluation and Research, presented on the FDA’s Biosimilar Action Plan.
While it is indeed the case that the current administration has made drug pricing and biosimilars a priority, and while the plan was hailed as a major step forward for biosimilars in the United States, “It’s not the only plan that’s going to exist,” said Christl.
She explained that the action plan, as put forth in the document announced by FDA Commissioner Scott Gottlieb, MD, in July of this year has served as the FDA’s way to bring together initiatives that the agency was already undertaking, and that the document is “not the end of what we’re going to do.” New elements may be added to the strategy, and new commitments may also be included in the future, she said.
Christl also reviewed the status of some of the planned deliverables for the 4 major elements of the plan:
Improving the efficiency of the biosimilar and interchangeable product development and approval process. As part of addressing this objective, the FDA will soon pilot its standardized review templates for biosimilars and will release an index of critical quality attributes.
Christl explained that the agency is working to develop and validate pharmacodynamic (PD) biomarkers in-house. She explained that current PD endpoints for products like filgrastim and pegfilgrastim relate well to clinical outcomes, but for rheumatology products, PD endpoints—such as B-cell depletion with rituximab—are less refined.
While the FDA has “had conversations about this” with developers, “we want to put resources behind this internally” to try to establish PD endpoints that will eliminate the need for developers to conduct large studies as one way to improve the efficiency of development.
Maximizing scientific and regulatory clarity for the biosimilar product development community. The FDA is well aware that the patent landscape or other factors may make it desirable for a biosimilar developer to seek approval for only some indications of a reference product, so the agency is working on guidance on carve-ins and carve-outs for indications that should give sponsors more clarity on this topic.
Another key deliverable for the FDA is an enhanced Purple Book. “Right now, it’s just 2 Excel spreadsheets,” Christl acknowledged. Given the variety of stakeholder needs for Purple Book development, “We’re likely going to push out a couple different versions” and seek feedback before arriving at a final version of the document.
Furthermore, the FDA is seeking to facilitate the use of non—US-licensed comparator products. “From day 1, we took an approach recognizing that [biosimilars] are global development projects,” said Christl, and the agency is assessing ways to address data-sharing agreements and legal issues that may affect the use of such products.
Developing effective communications to improve understanding of biosimilars among patients, providers, and payers. The agency is developing additional educational materials, including a 1-page document directed to patients, as well as video communications appropriate for use on social media.
Notably, the agency is also seeking to “move the education and outreach into school” for providers; the FDA wants providers to know, well before they enter practice, about the safety and efficacy of biosimilars. She likened current efforts to educate providers about these drugs to “Reading a drivers’ manual about how to dive your car, and then somebody putting you on the Autobahn.” She hopes that earlier education will eliminate some of the lack of provider knowledge about biosimilars observed currently.
Supporting market competition by reducing gaming of FDA requirements or other attempts to unfairly delay market competition to follow-on products. Finally, the agency is working to evaluate whether statutory or regulatory requirements are being used to inappropriately delay biosimilar of interchangeable competitors, and this process involves greater coordination with the Federal Trade Commission. It is also seeking to work together with legislators to address loopholes in current law. The FDA is able to provide technical support for legislation, Christl explained, that seeks to curb such practices as the refusal to sell samples of products for biosimilar testing.
Addressing Patent Abuse, Reimbursement Models Key to Sustainable Biosimilar Market
April 25th 2025Sonia T. Oskouei, PharmD, emphasized strategies to streamline regulations and evolve to overcome barriers and expand the availability of cost-effective biosimilar treatments across more therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Decade of Biosimilars Yields $36 Billion in Savings and Strengthens Supply Chain
April 24th 2025Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.